INShore: A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome

Sponsor

Hoffmann-La Roche (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05627557

Collaborator

(none)

Enrollment

Arms

41.5

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

This open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared with mycophenolate mofetil (MMF) in children and young adults (aged >= 2-25 years) with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).

Condition or Disease	Intervention/Treatment	Phase
Childhood Nephrotic Syndrome	Drug: Obinutuzumab Drug: MMF Drug: Prednisone Drug: Methylprednisolone Drug: Acetaminophen/ Paracetamol Drug: Diphenhydramine Hydrochloride	Phase 3

Study Design

Study Type:

Interventional

Anticipated Enrollment :

80 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase III, International, Multicenter, Randomised Open Label Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Patients With Childhood Onset Idiopathic Nephrotic Syndrome

Anticipated Study Start Date :

Feb 28, 2023

Anticipated Primary Completion Date :

Dec 1, 2025

Anticipated Study Completion Date :

Aug 15, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Obinutuzumab (Group A) Participants in Group A will receive obinutuzumab 1000 milligrams (mg) (or 20 mg/ kilogram [kg] for participants <45 kg) administered by intravenous (IV) infusion on Days 1, 15, 168 (Week 24), and 182 (Week 26).	Drug: Obinutuzumab Obinutuzumab will be administered as per schedule specified in the respective arm. Drug: Prednisone Participants taking prednisone or equivalent at randomization will follow a guided tapering schedule to reach the goal of 0mg/day by Weeks 4-6 (and no later than Week 8 following randomization and continue without prednisone through Week 52. Other Names: Non-Investigational Medicinal Product Drug: Methylprednisolone Methylprednisolone 80 mg (or 1.5 mg/kg if </=45 kg) IV will be administered as premedication prior to infusions. Other Names: Non-Investigational Medicinal Product Drug: Acetaminophen/ Paracetamol Acetaminophen 15 mg/kg (maximum dose 1000 mg) will be administered PO as premedication prior to infusions. Other Names: Non-Investigational Medicinal Product Drug: Diphenhydramine Hydrochloride Diphenhydramine HCl 0.5-1 mg/kg (maximum dose 50 mg) will be administered PO or IV as premedication prior to infusions. Other Names: Non-Investigational Medicinal Product
Experimental: MMF (Group B) Participants in Group B will receive oral MMF 600 mg/m^2 twice a day (BID) (target 1200 mg/m2/day in divided doses, maximum 2 g/day) to Week 52.	Drug: MMF MMF will be administered as per schedule specified in the respective arm. Drug: Prednisone Participants taking prednisone or equivalent at randomization will follow a guided tapering schedule to reach the goal of 0mg/day by Weeks 4-6 (and no later than Week 8 following randomization and continue without prednisone through Week 52. Other Names: Non-Investigational Medicinal Product

Arm

Intervention/Treatment

Experimental: Obinutuzumab (Group A)

Participants in Group A will receive obinutuzumab 1000 milligrams (mg) (or 20 mg/ kilogram [kg] for participants <45 kg) administered by intravenous (IV) infusion on Days 1, 15, 168 (Week 24), and 182 (Week 26).

Drug: Obinutuzumab

Obinutuzumab will be administered as per schedule specified in the respective arm.

Drug: Prednisone

Participants taking prednisone or equivalent at randomization will follow a guided tapering schedule to reach the goal of 0mg/day by Weeks 4-6 (and no later than Week 8 following randomization and continue without prednisone through Week 52.

Other Names:

Non-Investigational Medicinal Product

Drug: Methylprednisolone

Methylprednisolone 80 mg (or 1.5 mg/kg if </=45 kg) IV will be administered as premedication prior to infusions.

Other Names:

Non-Investigational Medicinal Product

Drug: Acetaminophen/ Paracetamol

Acetaminophen 15 mg/kg (maximum dose 1000 mg) will be administered PO as premedication prior to infusions.

Other Names:

Non-Investigational Medicinal Product

Drug: Diphenhydramine Hydrochloride

Diphenhydramine HCl 0.5-1 mg/kg (maximum dose 50 mg) will be administered PO or IV as premedication prior to infusions.

Other Names:

Non-Investigational Medicinal Product

Experimental: MMF (Group B)

Participants in Group B will receive oral MMF 600 mg/m^2 twice a day (BID) (target 1200 mg/m2/day in divided doses, maximum 2 g/day) to Week 52.

Drug: MMF

MMF will be administered as per schedule specified in the respective arm.

Drug: Prednisone

Other Names:

Non-Investigational Medicinal Product

Outcome Measures

Primary Outcome Measures

Percentage of Participants with Sustained Complete Remission at 1 year [At Week 52]

Secondary Outcome Measures

Overall Relapse Free Survival (RFS) [At Week 52]
Probability of RFS at Week 52 [At Week 52]
Cumulative Corticosteroid Dose (Prednisone or Equivalent Adjusted for Time on Study) [At Week 52]
Number of Relapses on Randomized Study Treatment [At Week 52]
Percentage of Participants Experiencing Edema Associated Relapse [At Week 52]
Percentage of Participants in Complete Remission at 18 Months [At Month 18]
Change in "General Fatigue" Domain of Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue Scale Total Score [Baseline to Week 52]
Change in "Physical Functioning" Domain of PedsQL Quality of Life Inventory [Baseline to Week 52]
Change in Cure Glomerulonephropathy (CureGN) Edema Scale [Baseline to Week 52]
Percentage of Participants with Adverse Events (AEs) [Baseline to Week 52]
Serum Concentrations of Obinutuzumab [At Days 1, 15 28, 84, 168, 182, 224, 364, and at Early Study Discontinuation Visit (unscheduled visit at the time of discontinuation from study, any time between Day 1 and Day 364)]
Percentage of Participants Achieving B Cell Depletion Highly Sensitive Flow Cytometry (HSFC) [At Days 1, 15, 28, 84, 168, 224, 364, and at Early Study Discontinuation Visit (unscheduled visit at the time of discontinuation from study, any time between Day 1 and Day 364)]
Total Peripheral B Cell and B Cell Subsets (e.g., Memory B Cells) Counts and Change from Baseline [At Days 1, 15, 28, 84, 168, 224, 364, and at Early Study Discontinuation Visit (unscheduled visit at the time of discontinuation from study, any time between Day 1 and Day 364)]

Eligibility Criteria

Criteria

Ages Eligible for Study:

2 Years to 25 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Diagnosis of frequently relapsing nephrotic syndrome (FRNS) or steroid dependent nephrotic syndrome (SDNS) before the age of 18 years
Must be in complete remission defined by the absence of edema, UPCR <= 0.2 g/g at screening and have three consecutive daily urine dipstick readings of trace or negative for protein within the week prior to randomization
Must have had at least one relapse in the 6 months prior to screening, after discontinuation of or while receiving oral corticosteroids and/or immunosuppressive therapy to prevent relapses
Participants having received cyclophosphamide in the 6 months prior to randomization must have experienced at least 1 relapse subsequent to cyclophosphamide discontinuation
Estimated glomerular filtration rate (eGFR) within normal range for age
For females of childbearing potential: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraception, during the treatment period and for 18 months after the final dose of obinutuzumab and for 6 weeks after the final dose of MMF
For males: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agree to refrain from donating sperm during the treatment period and for 90 days after the final dose of MMF

Exclusion Criteria:

Secondary nephrotic syndrome
History of steroid resistant nephrotic syndrome
History of genetic defects known to directly cause nephrotic syndrome
Treatment with other immunosuppressive medications to prevent relapse, other than MMF or oral corticosteroids within 2 months prior to randomization
Pregnancy or breastfeeding or intending to become pregnant during the study or within 18 months after the final dose of obinutuzumab, or within 6 weeks after the final dose of MMF
Females of childbearing potential, including those who have had a tubal ligation, must have a negative serum pregnancy test result within 28 days prior to initiation of study treatment and a negative urine pregnancy test at Day 1, prior to randomization
History of organ or bone marrow transplant
Participation in another therapeutic trial within 30 days of enrollment or 5 half-lives of the investigational drug
Intolerance or contraindication to study therapies
Participants demonstrating prior treatment failure to MMF as defined by two or more relapses in any 6-month period of time while receiving MMF for at least a 6-month duration
Participants in the judgment of the investigator likely to require systemic corticosteroids for reasons other than idiopathic nephrotic syndrome during the study
Active infection of any kind or any major episode of infection requiring hospitalization or treatment with IV anti-infective medications within 4 weeks prior to screening, or completion of oral anti-infectives within 2 weeks prior to randomization
History of or currently active primary or secondary immunodeficiency, including known history of human immunodeficiency virus (HIV) infection and other severe Immunodeficiency blood disorders
History of progressive multifocal leukoencephalopathy
History of or current cancer, including solid tumors, hematological malignancies, and carcinoma in situ within the past 5 years
Major surgery requiring hospitalization during the 4 weeks prior to screening or during screening
High risk for clinically significant bleeding or any condition requiring plasmapheresis, intravenous immunoglobulin, or acute blood product transfusions
Evidence of any significant or uncontrolled concomitant disease that, in the investigator's judgment, would preclude participant's participation, including but not limited to nervous system, respiratory, cardiac, hepatic, endocrine, malignant, or gastrointestinal disorders
Currently active alcohol or drug abuse or history of alcohol or drug abuse